Auteur : GRECC

Characterising heterogeneity in the use of different cannabis products : latent class analysis with 55 000 people who use cannabis and associations with severity of cannabis dependence, Sam Craft et al., 2019

Characterising heterogeneity in the use of different cannabis products : latent class analysis with 55 000 people who use cannabis and associations with severity of cannabis dependence Sam Craft, Adam Winstock, Jason Ferris, Clare Mackie, Michael T. Lynskey and Tom P. Freeman Psychological Medicine, 2019, 1–10. doi : 10.1017/S0033291719002460   Abstract Background. As new cannabis products and administration methods proliferate, patterns of use are becoming increasingly heterogeneous. However, few studies have explored different profiles of cannabis use and their association with problematic use. Methods. Latent class analysis (LCA) was used to identify subgroups of past-year cannabis users endorsing distinct patterns of use from a large international sample [...]

Lire la suite

Stroke in young cannabis users (18-49 years) : National trends in hospitalizations and outcomes, R. DESAI, 2019

Stroke in young cannabis users (18-49 years) : National trends in hospitalizations and outcomes DESAI R., SINGH S., PATEL K., GOVAL H., SHAH M., MANSURI Z., PATEL S., MAHUWALA Z.K., GOLDSTEIN L.B., QURESHI A.I. International Journal of Stroke, 2019, doi: 10.1177/1747493019895651 Abstract BACKGROUND : Recent legalization of therapeutic and recreational cannabis use makes it imperative to have an insight into odds and trends in young-onset stroke-related hospitalizations among cannabis users (18-49 years). METHODS : The National Inpatient Sample dataset (2007-2014) was utilized to assess national trends, odds of young-onset stroke-related hospitalizations, and outcomes among cannabis users vs. nonusers using provided discharge weights, strata, and cluster design. [...]

Lire la suite

Beta-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain, Esraa Aly et al.,

Beta-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain Esraa Aly, Maitham A. Khajah and Willias Masocha Molecules, 2020, 25, 106; doi:10.3390/molecules25010106   Abstract : Neuropathic pain associated with nucleoside reverse transcriptase inhibitors (NRTIs), therapeutic agents for human immunodeficiency virus (HIV), responds poorly to available drugs. Smoked cannabis was reported to relieve HIV-associated neuropathic pain in clinical trials. Some constituents of cannabis (Cannabis sativa) activate cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors. However, activation of the CB1 receptor is associated with side eects such as psychosis and physical dependence. Therefore, we investigated the effect of B-caryophyllene (BCP), [...]

Lire la suite

Prolonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor Performance and Anxiety in C57BL/6J Mice, Eva M. Schleicher et al., 2019

Prolonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor Performance and Anxiety in C57BL/6J Mice Eva M. Schleicher, Frederik W. Ott, Melanie Müller, Barbara Silcher, Marius E. Sichler, Maximilian J. Löw, Jannek M. Wagner and Yvonne Bouter Frontiers in Behavioral Neuroscience, 2019, Volume 13, Article 94 doi : 10.3389/fnbeh.2019.00094   The Cannabis plant contains more than 100 currently known phytocannabinoids. Regarding the rising consumption of the non-psychotropic phytocannabinoid cannabidiol (CBD) in people’s everyday life (e.g., beauty products, food and beverages), the importance of studies on the influence of CBD on healthy humans and rodents is evident. Therefore, the behavioral profile of CBD was investigated with [...]

Lire la suite

The European Congress on Legal and Regulations in Cannabis, Vienna, Austria,13-14 February 2020

The European Congress on Legal and Regulations in Cannabis Vienna, Austria 13-14 February 2020 Dear Colleagues, It is with great pleasure that we invite you to attend The European Congress on Legal and Regulations in Cannabis (LR-Cannabis) taking place 13-14 February 2020 in Vienna, Austria.   The Congress aim is to learn more about the requirements and processes of medical cannabis under the law and other regulations, as well as to present valuable professional knowledge.   READ MORE

Lire la suite

As CBD Oil Flirts with Mainstream, Questions Mount, Kathleen Doheny, Medscape, 2018

As CBD Oil Flirts with Mainstream, Questions Mount Kathleen Doheny Medscape, June 11, 2018 Anxiety is a given for Jessica Singer, 25, who juggles her job at a marijuana dispensary with her night-time gigs as a stand-up comedian in Los Angeles. So when it’s time for bed, "I can't turn off my brain,'' she says. Now she does, with the help of a new bedtime ritual -- a ''snack" of two gummy bears containing CBD. CBD, or cannabidiol, is a substance from marijuana that lacks the ''high'' of the THC (tetrahydro-cannabinol) also found in marijuana. The remedy is affordable for her -- about $35 [...]

Lire la suite

A Physician’s Guide to the Cannabidiol Craze, Angela Coombs & Diana M. Martinez, 2013

COMMENTARY A Physician's Guide to the Cannabidiol Craze Angela Coombs, MD; Diana M. Martinez, MD Medscape, May 31, 2019 Last month at the Columbia University Department of Psychiatry in upper Manhattan, Columbia chief psychiatry resident Dr Angela Coombs interviewed addiction expert Dr Diana Martinez on a number of issues related to the rising popularity and usage of cannabidiol (CBD). This transcript has been edited for clarity.   Angela Coombs, MD: Hi. My name is Dr Angela Coombs and I'm a chief resident here at Columbia. We are so happy to be able to have Dr Diana Martinez, who's a professor in psychiatry at Columbia and an expert [...]

Lire la suite

‘Standard THC units’: a proposal to standardize dose across all cannabis products and methods of administration, T.P. Freeman & V.Lorenzetti, 2019

'Standard THC units': a proposal to standardize dose across all cannabis products and methods of administration T.P. Freeman, V.Lorenzetti Addictions, 2019, Oct 12. doi : 10.1111/add.14842 © 2019 Society for the Study of Addiction. Abstract BACKGROUND AND AIMS : Cannabis products are becoming increasingly diverse, and vary considerably in concentrations of ∆9 -tetrahydrocannabinol (THC) and cannabidiol (CBD). Higher doses of THC can increase the risk of harm from cannabis, while CBD may partially offset some of these effects. Lower Risk Cannabis Use Guidelines currently lack recommendations based on quantity of use, and could be improved by implementing standard units. However, there is currently no consensus on [...]

Lire la suite

Bibliographie CANNABINOÏDES et Traitement des Nausées et Vomissements, Docteur Christian SUEUR, GRECC, 2e édition, janvier 2020

Bibliographie CANNABINOÏDES et Traitement des Nausées et Vomissements   Docteur Christian SUEUR, GRECC, 2e édition, janvier 2020.   Le Cannabis comme anti-émétique :   Les prescriptions médicales, chez les adultes (THC naturel ou synthétique - Nabilone) comme chez les enfants (delta 8-THC, Abrahamov et al, 1995), ont débutées dès 1975. L’efficacité a été prouvée dans de nombreux essais cliniques, et de nombreuses méta-analyses (8/9 pour le cannabis et 3/3 pour le Nabilone, Penta et al, 1981). Par contre les effets psychotropiques peuvent être mal supportés par de nombreux patients, et justifie l’arrêt, ou la diminution des doses. Les associations variables THC/CBD présente un intérêt probable. Aucun effet indésirable persistant ou fatal [...]

Lire la suite

Cannabis in Cancer Care, D.I. Abrams and M. Guzman, 2015

Cannabis in Cancer Care D.I. Abrams and M. Guzman Clinical Pharmacology & Therapeutics, 2015, 97, (6), 575-586. Doi : 10.1002/cpt.108   Cannabis has been used inmedicine for thousands of years prior to achieving its current illicit substance status. Cannabinoids, the active components of Cannabis sativa,mimic the effects of the endogenous cannabinoids (endocannabinoids), activating specific cannabinoid receptors, particularly CB1 found predominantly in the central nervous system and CB2 found predominantly in cells involved with immune function. Delta-9-tetrahydrocannabinol, themain bioactive cannabinoid in the plant, has been available as a prescriptionmedication approved for treatment of cancer chemotherapy-induced nausea and vomiting and anorexia associated with the AIDS wasting syndrome. Cannabinoidsmay [...]

Lire la suite